{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:09:23Z","timestamp":1793383763345,"version":"4.5.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Objective To investigate the differences in scalp and gut microbial diversity, community structure, and specific microbial species in patients with psoriasis vulgaris before and after treatment with interleukin (IL)-17A inhibitors, compared to healthy individuals. Additionally, the preliminary impact of IL-17A inhibitors on scalp and gut microecology was explored. Methods This study utilized 16S rRNA gene sequencing to comparatively analyze the dynamic changes in scalp and gut microbiota diversity and community composition in patients with moderate-to-severe psoriasis vulgaris before and after treatment with IL-17A inhibitors. The study included 15 patients with a Psoriasis Area and Severity Index score of \u226510 and a sex- and age-matched healthy control group. Scalp scale and fecal samples were collected at three-time points: pre-treatment (baseline), 4 weeks post-treatment, and 12 weeks post-treatment. Results IL-17A inhibitors demonstrated favorable efficacy in treating plaque psoriasis. Following treatment, no statistically significant difference was observed in the alpha and beta diversity of the scalp microbiome between patients with psoriasis and healthy controls. Notably, the abundance of harmful bacteria (<jats:italic>Pseudomonas<\/jats:italic> species) decreased on the scalp, while beneficial <jats:italic>Bifidobacterium<\/jats:italic> levels increased. Regarding gut microbiota, significant differences in \u03b1-diversity richness were observed compared to healthy controls (P&amp;lt;0.05). Moreover, the abundance of <jats:italic>Roseburia<\/jats:italic>, <jats:italic>Megamonas<\/jats:italic>, and the phylum <jats:italic>Bacteroidota<\/jats:italic> increased, although the Firmicutes\/Bacteroidota (F\/B) ratio showed no significant change. Conclusion: IL-17A inhibitor therapy has the potential to improve the structure and diversity of the scalp microbiome, gradually restoring it toward a healthier state while also enhancing gut microbiota diversity. These therapeutic effects may be mediated through immune regulation, such as the Th17 pathway modulation, and microbial metabolites like short-chain fatty acids.<\/jats:p>","DOI":"10.3389\/fcimb.2025.1623003","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T05:22:08Z","timestamp":1759728128000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The impact of IL-17A inhibitors on scalp and gut microbiota in psoriasis"],"prefix":"10.3389","volume":"15","author":[{"given":"Wenxia","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/exd.14091","article-title":"An update on the microbiology, immunology and genetics of seborrheic dermatitis","volume":"29","author":"Adalsteinsson","year":"2020","journal-title":"Exp. Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3390\/life15030425","article-title":"Hard-to-treat areas in psoriasis: an underevaluated part of the disease","volume":"15","author":"Adina","year":"2025","journal-title":"Life (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/bjd\/ljad004","article-title":"Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR","volume":"188","author":"Alabas","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2174\/1389202923666220527111037","article-title":"Etiopathogenesis of psoriasis from genetic perspective: an updated review","volume":"23","author":"Babaie","year":"2022","journal-title":"Curr. Genomics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jaad.2017.05.033","article-title":"The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study","volume":"77","author":"Bagel","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s40168-018-0533-1","article-title":"Alteration of the cutaneous microbiome in psoriasis and potential role in Th17 polarization","volume":"6","author":"Chang","year":"2018","journal-title":"Microbiome"},{"key":"B8","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-\u03b1 in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"7133","DOI":"10.3390\/jcm11237133","article-title":"Severe scalp psoriasis microbiome has increased biodiversity and relative abundance of pseudomonas compared to mild scalp psoriasis","volume":"11","author":"Choi","year":"2022","journal-title":"J. Clin. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1038\/s41598-018-22125-y","article-title":"Gut microbial composition in patients with psoriasis","volume":"8","author":"Codo\u00f1er","year":"2018","journal-title":"Sci. Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"12754","DOI":"10.1038\/s41598-020-69537-3","article-title":"Metagenomic analysis of gut microbiota in non-treated plaque psoriasis patients stratified by disease severity: Development of a new soriasis-Microbiome Index","volume":"10","author":"Dei-Cas","year":"2020","journal-title":"Sci. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1194\/jlr.R036012","article-title":"The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism","volume":"54","author":"den Besten","year":"2013","journal-title":"J. Lipid Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1684\/ejd.2012.1802","article-title":"Prevalence of psoriasis in China:a population -based study in six cities","volume":"22","author":"Ding","year":"2012","journal-title":"Eur. J. Dermatol."},{"key":"B14","first-page":"396\u2013400","article-title":"Natural history and treatment of scalp psoriasis","volume":"49","author":"Farber","year":"1992","journal-title":"Cutis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3390\/pathogens10020211","article-title":"Microbiota and drug response in Inflammatory Bowel Disease","volume":"10","author":"Franzin","year":"2021","journal-title":"Pathogens"},{"key":"B16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/exd.12572","article-title":"Psoriasis is not an autoimmune disease","volume":"24","author":"Fry","year":"2015","journal-title":"Exp. Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e12846","DOI":"10.1111\/sji.12846","article-title":"The CCL20 and CCR6 axis in psoriasis","volume":"91","author":"Furue","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"4703","DOI":"10.1038\/s41467-019-12253-y","article-title":"Microbe-host interplay in atopic dermatitis and psoriasis","volume":"10","author":"Fyhrquist","year":"2019","journal-title":"Nat. Commun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Clin. Trial"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1111\/bjd.15610","article-title":"The global state of psoriasis disease epidemiology: a workshop report","volume":"177","author":"Griffiths","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/43088","article-title":"A peptide antibiotic from human skin","volume":"387","author":"Harder","year":"1997","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1165\/ajrcmb.22.6.4023","article-title":"Mucoid Pseudomonas aeruginosa, TNF-\u03b1, and IL-1 \u03b2, but Not IL-6, induce human \u03b2-defensin-2 in respiratory epithelia","volume":"22","author":"Harder","year":"2000","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/ng.2007.48","article-title":"Psoriasis is associated with increased \u03b2-defensin genomic copy number","volume":"40","author":"Hollox","year":"2008","journal-title":"Nat. Genet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"738","DOI":"10.25259\/IJDVL_323_21","article-title":"Is cutaneous microbiota a player in disease pathogenesis? Comparison of cutaneous microbiota in psoriasis and seborrheic dermatitis with scalp involvement","volume":"88","author":"Kay\u0131ran","year":"2022","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/jdv.14721","article-title":"Endosymbiosis and its significance in dermatology","volume":"32","author":"Kubiak","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1111\/jdv.12996","article-title":"Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis","volume":"29","author":"Langley","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1036196","article-title":"Bacteroides vulgatus attenuates experimental mice colitis through modulating gut microbiota and immune responses","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/life15030425","article-title":"Hard-to-treat areas in psoriasis: an underevaluated part of the disease","volume":"15","author":"Lupulescu","year":"2025","journal-title":"Life (Basel)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e41672","DOI":"10.1016\/j.heliyon.2025.e41672","article-title":"New horizons in the treatment of psoriasis: modulation of gut microbiome","volume":"11","author":"Memariani","year":"2025","journal-title":"Heliyon"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e12589","DOI":"10.1111\/dth.12589","article-title":"Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails","volume":"31","author":"Merola","year":"2018","journal-title":"Dermatol. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"101494","DOI":"10.1016\/j.berh.2020.101494","article-title":"The gut microbiome in psoriasis and psoriatic arthritis","volume":"33","author":"Myers","year":"2019","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.jid.2017.12.029","article-title":"The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch","volume":"138","author":"Nattkemper","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.3390\/life12122050","article-title":"Psoriasis management challenges regarding difficult-to-treat areas: therapeutic decision and effectiveness","volume":"12","author":"Nicolescu","year":"2022","journal-title":"Life (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-025-01211-9","article-title":"The human skin microbiome: from metagenomes to therapeutics","author":"Oh","year":"2025","journal-title":"Nat. Rev. Microbiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/bjd.12110","article-title":"Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis:a randomized, doubleblind, placebo-controlled phase II dose-ranging study","volume":"168","author":"Pappka","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1185523","article-title":"Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO)","volume":"10","author":"Piaserico","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4529","DOI":"10.3390\/ijms22094529","article-title":"Psoriasis and gut microbiome-current state of art","volume":"22","author":"Polak","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"573","DOI":"10.35541\/cjd.20220839","article-title":"Guidelines for the diagnosis and treatment of psoriasis in China (2023 edition)","volume":"7","year":"2023"},{"key":"B39","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jaad.2019.06.024","article-title":"Psoriatic lesions are characterized by higher bacterial load and imbalance between Cutibacterium and Corynebacterium","volume":"82","author":"Quan","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/jdv.12562","article-title":"Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review","volume":"28","author":"Rouzaud","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.anaerobe.2005.05.001","article-title":"A dynamic partnership: Celebrating our gut flora","volume":"11","author":"Sears","year":"2005","journal-title":"Anaerobe"},{"key":"B42","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3390\/microorganisms8060874","article-title":"Changes in the intestinal microbiota of patients with Inflammatory Bowel Disease with clinical remission during an 8-Week infliximab infusion cycle","volume":"8","author":"Seong","year":"2020","journal-title":"Microorganisms"},{"key":"B43","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/pathogens9060463","article-title":"Gut microbiome in psoriasis: an updated review","volume":"9","author":"Sikora","year":"2020","journal-title":"Pathogens"},{"key":"B44","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3109\/09546634.2010.519376","article-title":"Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice","volume":"23","author":"Sola-Ortigosa","year":"2012","journal-title":"J. Dermatolog. Treat."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/jamadermatol.2019.2613","article-title":"Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab","volume":"155","author":"Soria","year":"2019","journal-title":"JAMA Dermatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"684690","DOI":"10.1001\/jamadermatol.2021.0734","article-title":"Long-term outcomes and prognosis in new-onset psoriasis","volume":"157","author":"Svedbom","year":"2021","journal-title":"JAMA Dermatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/exd.13463","article-title":"The Akkermansia muciniphila is a gut microbiota signature in psoriasis","volume":"27","author":"Tan","year":"2018","journal-title":"Exp. Dermatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1177\/1203475417711124","article-title":"Unilateral blepharitis with fine follicular scaling","volume":"21","author":"Tatu","year":"2017","journal-title":"J. Cutan Med. Surg."},{"key":"B49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00128071-200102030-00005","article-title":"Psoriasis of the scalp. Diagnosis and management","volume":"2","author":"van de Kerkhof","year":"2001","journal-title":"Am. J. Clin. Dermatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nmicrobiol.2017.26","article-title":"An insider\u2019s perspective: Bacteroides as a window into the microbiome","volume":"2","author":"Wexler","year":"2017","journal-title":"Nat. Microbiol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jaad.2020.08.060","article-title":"Modifiable lifestyle and environmental factors associated with onset of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational studies","volume":"84","author":"Xie","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"B52","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.3390\/nu15081952","article-title":"Dose-response efficacy and mechanisms of orally administered bifidobacterium breve CCFM683 on IMQ-induced psoriasis in mice","volume":"15","author":"Xinqi","year":"2023","journal-title":"Nutrients"},{"key":"B53","doi-asserted-by":"publisher","first-page":"5464","DOI":"10.1007\/s12325-023-02672-1","article-title":"Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study","volume":"40","author":"Ying","year":"2022","journal-title":"Adv Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1161\/CIRCULATIONAHA.118.033714","article-title":"Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis","volume":"138","author":"Yoshida","year":"2018","journal-title":"Circulation"},{"key":"B55","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/mi.2016.75","article-title":"Mechanisms of inflammation-driven bacterial dysbiosis in the gut","volume":"10","author":"Zeng","year":"2017","journal-title":"Mucosal Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e14890","DOI":"10.1111\/exd.14890","article-title":"Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real-world practice","volume":"33","author":"Zhou","year":"2024","journal-title":"Exp. Dermatol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1623003\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T05:22:09Z","timestamp":1759728129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1623003\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":56,"alternative-id":["10.3389\/fcimb.2025.1623003"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1623003","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"article-number":"1623003"}}